Efficacy and Safety of iGlarLixi Versus Standard of Care in a Real-world Adult China Population With Uncontrolled Type 2 Diabetes on Oral Agents

NCT07307235 · clinicaltrials.gov ↗

PHASE4

Phase

NOT_YET_RECRUITING

Status

1316

Enrollment

OTHER

Sponsor class

Conditions

Type 2 Diabetes

Interventions

DRUG: iGlarLixi (insulin glargine/lixisenatide)
DRUG: standard of care (basal insulin or premixed insulin, excluding any GLP-1 receptor agonist-containing drugs)

Sponsor

Shanghai Zhongshan Hospital

Collaborators

[object Object]